Gerold Bongers1, Luciana R Muniz1, Michelle E Pacer1, Alina C Iuga2, Nanthakumar Thirunarayanan1, Erik Slinger1, Martine J Smit3, E Premkumar Reddy4, Lloyd Mayer1, Glaucia C Furtado1, Noam Harpaz2, Sergio A Lira5. 1. Immunology Institute, Mount Sinai School of Medicine, New York, New York. 2. Division of Gastrointestinal Pathology, Department of Pathology, The Mount Sinai Medical Center, New York, New York. 3. Leiden/Amsterdam Center for Drug Research, Division of Medicinal Chemistry, Faculty of Sciences, VU University Amsterdam, Amsterdam, The Netherlands. 4. Department of Oncological Sciences, Mount Sinai School of Medicine, New York, New York. 5. Immunology Institute, Mount Sinai School of Medicine, New York, New York. Electronic address: sergio.lira@mssm.edu.
Abstract
BACKGROUND & AIMS: Epithelial cancers can be initiated by activating mutations in components of the mitogen-activated protein kinase signaling pathway such as v-raf murine sarcoma viral oncogene homolog B1 (BRAF), v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS), or epidermal growth factor receptor (EGFR). Human intestinal serrated polyps are a heterogeneous group of benign lesions, but some progress to colorectal cancer. Tumors that arise from these polyps frequently contain activating mutations in BRAF or KRAS, but little is known about the role of EGFR activation in their development. METHODS: Polyp samples were obtained from adults during screening colonoscopies at Mount Sinai Hospital in New York. We measured levels of EGFR protein and phosphorylation in human serrated polyps by immunohistochemical and immunoblot analyses. We generated transgenic mice that express the ligand for EGFR, Heparin-binding EGF-like growth factor (HB-EGF), in the intestine. RESULTS: EGFR and the extracellular-regulated kinases (ERK)1/2 were phosphorylated in serrated areas of human hyperplastic polyps (HPPs), sessile serrated adenomas, and traditional serrated adenomas. EGFR and ERK1/2 were phosphorylated in the absence of KRAS or BRAF activating mutations in a subset of HPP. Transgenic expression of the EGFR ligand HB-EGF in the intestines of mice promoted development of small cecal serrated polyps. Mice that expressed a combination of HB-EGF and US28 (a constitutively active, G-protein-coupled receptor that increases processing of HB-EGF from the membrane) rapidly developed large cecal serrated polyps. These polyps were similar to HPPs and had increased phosphorylation of EGFR and ERK1/2 within the serrated epithelium. Administration of pharmacologic inhibitors of EGFR or MAPK to these transgenic mice significantly reduced polyp development. CONCLUSIONS: Activation of EGFR signaling in the intestine of mice promotes development of serrated polyps. EGFR signaling also is activated in human HPPs, sessile serrated adenomas, and traditional serrated adenomas.
BACKGROUND & AIMS:Epithelial cancers can be initiated by activating mutations in components of the mitogen-activated protein kinase signaling pathway such as v-raf murine sarcoma viral oncogene homolog B1 (BRAF), v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS), or epidermal growth factor receptor (EGFR). Human intestinal serrated polyps are a heterogeneous group of benign lesions, but some progress to colorectal cancer. Tumors that arise from these polyps frequently contain activating mutations in BRAF or KRAS, but little is known about the role of EGFR activation in their development. METHODS: Polyp samples were obtained from adults during screening colonoscopies at Mount Sinai Hospital in New York. We measured levels of EGFR protein and phosphorylation in human serrated polyps by immunohistochemical and immunoblot analyses. We generated transgenic mice that express the ligand for EGFR, Heparin-binding EGF-like growth factor (HB-EGF), in the intestine. RESULTS:EGFR and the extracellular-regulated kinases (ERK)1/2 were phosphorylated in serrated areas of humanhyperplastic polyps (HPPs), sessile serrated adenomas, and traditional serrated adenomas. EGFR and ERK1/2 were phosphorylated in the absence of KRAS or BRAF activating mutations in a subset of HPP. Transgenic expression of the EGFR ligand HB-EGF in the intestines of mice promoted development of small cecal serrated polyps. Mice that expressed a combination of HB-EGF and US28 (a constitutively active, G-protein-coupled receptor that increases processing of HB-EGF from the membrane) rapidly developed large cecal serrated polyps. These polyps were similar to HPPs and had increased phosphorylation of EGFR and ERK1/2 within the serrated epithelium. Administration of pharmacologic inhibitors of EGFR or MAPK to these transgenic mice significantly reduced polyp development. CONCLUSIONS: Activation of EGFR signaling in the intestine of mice promotes development of serrated polyps. EGFR signaling also is activated in human HPPs, sessile serrated adenomas, and traditional serrated adenomas.
Authors: Gerold Bongers; David Maussang; Luciana R Muniz; Vanessa M Noriega; Alberto Fraile-Ramos; Nick Barker; Federica Marchesi; Nanthakumar Thirunarayanan; Henry F Vischer; Lihui Qin; Lloyd Mayer; Noam Harpaz; Rob Leurs; Glaucia C Furtado; Hans Clevers; Domenico Tortorella; Martine J Smit; Sergio A Lira Journal: J Clin Invest Date: 2010-10-11 Impact factor: 14.808
Authors: Moritz Bennecke; Lydia Kriegl; Monther Bajbouj; Kristin Retzlaff; Sylvie Robine; Andreas Jung; Melek C Arkan; Thomas Kirchner; Florian R Greten Journal: Cancer Cell Date: 2010-08-09 Impact factor: 31.743
Authors: Sung Hee Lee; Li-Li Hu; Jose Gonzalez-Navajas; Geom Seog Seo; Carol Shen; Jonathan Brick; Scott Herdman; Nissi Varki; Maripat Corr; Jongdae Lee; Eyal Raz Journal: Nat Med Date: 2010-05-09 Impact factor: 53.440
Authors: Yinfei Yin; Anna M Grabowska; Philip A Clarke; Elisabeth Whelband; Karen Robinson; Richard H Argent; Amanda Tobias; Rajendra Kumari; John C Atherton; Susan A Watson Journal: Gut Date: 2010-06-28 Impact factor: 23.059
Authors: Linda A S Carragher; Kimberley R Snell; Susan M Giblett; Victoria S S Aldridge; Bipin Patel; Simon J Cook; Doug J Winton; Richard Marais; Catrin A Pritchard Journal: EMBO Mol Med Date: 2010-11 Impact factor: 12.137
Authors: Meng-Han Wu; Marco Padilla-Rodriguez; Isabella Blum; Abigail Camenisch; Vanessa Figliuolo da Paz; Matthew Ollerton; John Muller; Samina Momtaz; Stefanie A T Mitchell; Pawel Kiela; Curtis Thorne; Jean M Wilson; Christopher M Cox Journal: Dev Biol Date: 2021-08-17 Impact factor: 3.582
Authors: Jean-Pierre Raufman; Paul A Dawson; Anuradha Rao; Cinthia B Drachenberg; Jonathon Heath; Aaron C Shang; Shien Hu; Min Zhan; James E Polli; Kunrong Cheng Journal: Carcinogenesis Date: 2015-07-25 Impact factor: 4.944
Authors: Manuel Tardáguila; Emilia Mira; Miguel A García-Cabezas; Anna M Feijoo; Miguel Quintela-Fandino; Iñigo Azcoitia; Sergio A Lira; Santos Mañes Journal: Cancer Res Date: 2013-05-29 Impact factor: 12.701
Authors: Gerold Bongers; Michelle E Pacer; Thais H Geraldino; Lili Chen; Zhengxiang He; Daigo Hashimoto; Glaucia C Furtado; Jordi Ochando; Kevin A Kelley; Jose C Clemente; Miriam Merad; Harm van Bakel; Sergio A Lira Journal: J Exp Med Date: 2014-03-03 Impact factor: 14.307